跳至主要内容
临床试验/NCT00041249
NCT00041249已完成2 期

Efficacy And Safety Study Of Brostallicin In Patients With Locally Advanced Or Metastatic Soft Tissue Sarcoma Failing One Prior Chemotherapy Treatment

European Organisation for Research and Treatment of Cancer - EORTC32 个研究点 分布在 5 个国家目标入组 64 人开始时间: 2002年5月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
64
试验地点
32

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of brostallicin in treating patients who have locally advanced or metastatic soft tissue sarcoma that has not responded to one previous chemotherapy regimen.

详细描述

OBJECTIVES:

  • Determine the antitumor activity of brostallicin, in terms of objective response, in patients with locally advanced or metastatic soft tissue sarcoma who have failed one prior chemotherapy treatment.
  • Determine the time to progression and duration of response in patients treated with this drug.
  • Determine the safety and toxic effects of this drug in these patients.
  • Correlate clinical outcome with whole blood glutathione level in patients treated with this drug.

OUTLINE: This is a multicenter study. Patients are stratified according to tumor (tumors other than gastrointestinal stromal tumor (GIST) vs GIST).

Patients receive brostallicin IV over 10 minutes on day 1. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 2 months for 1 year and then every 4 months for 1 year.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
15 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Network
责任方
Sponsor

研究点 (32)

Loading locations...

相似试验

Brostallicin in Treating Patients With Locally... | 临床试验